Bradley Canino
Stock Analyst at Stifel
(1.13)
# 3,546
Out of 4,853 analysts
89
Total ratings
28.75%
Success rate
-11.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.54 | +490.55% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $0.53 | +180.85% | 8 | Mar 7, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $3.25 | +607.69% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $6.95 | +633.81% | 6 | Feb 12, 2025 | |
| JANX Janux Therapeutics | Maintains: Buy | $70 → $115 | $25.13 | +357.62% | 2 | Dec 3, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $41 | $10.96 | +274.09% | 5 | Oct 14, 2024 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $6.45 | +194.57% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $11.98 | +250.58% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $19.56 | +104.50% | 4 | Sep 25, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $115 → $135 | $76.79 | +75.82% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $9.08 | +120.26% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.28 | +681.25% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.50 | +566.67% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $57.58 | +71.93% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $1.54 | +809.09% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $9.07 | +341.01% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $130 | $128.10 | +1.48% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $44.26 | +24.27% | 4 | Feb 23, 2024 | |
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.54
Upside: +490.55%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $0.53
Upside: +180.85%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $3.25
Upside: +607.69%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $6.95
Upside: +633.81%
Janux Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $70 → $115
Current: $25.13
Upside: +357.62%
Syndax Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $40 → $41
Current: $10.96
Upside: +274.09%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $6.45
Upside: +194.57%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $11.98
Upside: +250.58%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $19.56
Upside: +104.50%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $76.79
Upside: +75.82%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $9.08
Upside: +120.26%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.28
Upside: +681.25%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.50
Upside: +566.67%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $57.58
Upside: +71.93%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $1.54
Upside: +809.09%
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $9.07
Upside: +341.01%
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $128.10
Upside: +1.48%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $44.26
Upside: +24.27%